We know you’re concerned about seizures

We also know seizures aren’t your only concern.

What Makes TOPAMAX Different

TOPAMAX for Epilepsy

TOPAMAX can make a significant difference in the lives of people with epilepsy. TOPAMAX provides a proven safety and efficacy profile , and is generally well-tolerated seizure control for many kinds of seizures—including some of the most severe.

Some benefits of using TOPAMAX are listed below.

TOPAMAX Has a Proven Safety Profile

TOPAMAX has a proven safety profile. Healthcare professionals have extensive clinical experience with TOPAMAX. Topiramate has been available in the United States since 1997 and in parts of Europe since 1995, regardless of condition.

Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.

Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.

More common side effects in adults are nervousness, coordination problems, fatigue, speech problems, slowed thinking, memory difficulty, tingling in arms and legs, and double vision; and in children, fatigue, loss of appetite, nervousness, memory difficulty, aggressive behavior, and weight loss.

As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50 mg/day group) in adults were tingling in arms and legs, weight decrease, sleepiness, loss of appetite, dizziness, and difficulty with memory; and in children, weight decrease, upper respiratory tract infection, tingling in arms and legs, loss of appetite, diarrhea, and mood problems.

In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were sleepiness, dizziness, nervousness, loss of muscle coordination, fatigue, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, tingling in arms and legs, and double vision; and in children (5 to 9 mg/kg/day), fatigue, sleepiness, loss of appetite, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.

^ Return to Top

TOPAMAX Has Helped Millions of People

More than 4 million patients worldwide have been treated with topiramate since 1995, regardless of condition.

^ Return to Top

TOPAMAX Works Well With Other Antiepileptic Drugs

When used in combination with other antiepileptic drugs, TOPAMAX has been proven to be effective at controlling seizures in adults and children (age 2 or older) who have:

^ Return to Top

Topamax Has Lower Potential for Interaction With Most Other Medicines

Because TOPAMAX interacts only slightly with most other drugs, it can be taken along with many other common medications.

^ Return to Top

TOPAMAX Has Minimal Interference With Hormonal Contraceptives, Such as the Pill, at Lower Doses

TOPAMAX does not interact in any significant way with combination oral contraceptives (which use the hormones progestin and estrogen) at doses of TOPAMAX as high as 200 mg/day. There is no effect on the hormone progestin for any dose that has been studied. For doses of TOPAMAX between 200 mg/day and 800 mg/day, exposure to the estrogen in the contraceptive lessens, which may weaken the effect of the contraceptive or lead to breakthrough bleeding.

Note: Report any change in your bleeding patterns to the healthcare professional who prescribed your contraceptive, and let her or him know you are taking TOPAMAX. Check with your healthcare professional about all of the medicines you take along with TOPAMAX, including birth control.

^ Return to Top

TOPAMAX Is Not Associated With Drug-Induced Weight Gain

Even small weight gain within the range of healthy weights can carry health risks. TOPAMAX is not associated with any drug-induced weight gain.

^ Return to Top

TOPAMAX Can Be Taken With or Without Food

TOPAMAX is absorbed rapidly. Food does not interfere with its effectiveness.

^ Return to Top

TOPAMAX Offers Treatment Support

Treatment support can make a difference. If you or your loved one are taking TOPAMAX, join the FREE Everyday Essentials™ support program and learn how to get the most out of your treatment. Benefits include expert answers to your treatment questions, product rebates, support giver information, help finding resources in your area—and much more.

^ Return to Top

About TOPAMAX

TOPAMAX is approved as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

TOPAMAX is approved as add-on therapy for patients 2 years of age and older with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.

Important Safety Information

Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.

Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.

More common side effects in adults are nervousness, coordination problems, fatigue, speech problems, slowed thinking, memory difficulty, tingling in arms and legs, and double vision; and in children, fatigue, loss of appetite, nervousness, memory difficulty, aggressive behavior, and weight loss.

As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50 mg/day group) in adults were tingling in arms and legs, weight decrease, sleepiness, loss of appetite, dizziness, and difficulty with memory; and in children, weight decrease, upper respiratory tract infection, tingling in arms and legs, loss of appetite, diarrhea, and mood problems.

In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were sleepiness, dizziness, nervousness, loss of muscle coordination, fatigue, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, tingling in arms and legs, and double vision; and in children (5 to 9 mg/kg/day), fatigue, sleepiness, loss of appetite, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.

Tell your doctor about other medications you take.

Please see full U.S. Prescribing Information.

© Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1999-2008. All rights reserved.

Your use of the information on this site is subject to the terms of our Legal Statement. Please see our Privacy Policy.

This site is published by Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which is solely responsible for its contents.

Capitalized product names are trademarks of Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

This information is intended for use by our customers, patients and healthcare professionals in the United States only. Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

This site was last modified on: Jul 26 2007 at 13:45:29 EDT